Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Numan deploys Titan software to drive efficiency

To increase efficiency savings, digital men's health provider Numan has joined forces with Invatech Health to deploy the health tech company's cutting-edge software Titan.

Launched in early 2019, Numan provides medication for 175,000 patients via its Cardiff-based fulfilment operation. A team of its clinicians create personalised treatment plans for the most common male health concerns.


In a statement, Invatech said its Titan software could deliver 20 per cent efficiency savings for Numan whilst supporting the company's ambitious growth plans with improved safety and scalability in processing medications. The new partnership also comes alongside 100 new contracts with community pharmacies around the UK.

Andrew Caple, director of Pharmacy Operations at of Numan, said: “Our findings show that three quarters of men will not visit a doctor when they have a health concern, and we therefore recognize that the online market provides a great opportunity to tackle these problems.

“As expected, we are experiencing significant growth and we needed fulfilment software which could support our current operations and future ambitions.

“We’re therefore delighted to have Titan on board and are already impressed by the impact it is having. With the increase in efficiency and safety, it’s the perfect partner for the next stage in our growth.”

Titan is a cutting edge Patient Medication Record (PMR) system which in late 2019 became the first PMR to be given NHS accreditation in more than a decade.

It is an entirely new, innovative, cloud-based solution that manages end-to-end workflow within pharmacies, releasing valuable pharmacist time and giving control back to the business.

The brainchild of former community pharmacist turned tech pioneer Tariq Muhammad, Titan is now making waves among innovative sector start-ups which are using automation, apps and robotics to change the way medication is delivered to patients.

Earlier this year, Invatech Health announced a further £950,000 loan from Innovate UK, under a programme to support game-changing innovations in the UK’s SME community.

Muhammad, who is CEO of Invatech Health, said: “We’re delighted with the progress of our business in 2021,  as we continue to make waves across our two key sectors – innovative online businesses and community pharmacy.

“Both Numan and ourselves are at the forefront of tech innovation in the pharmacy sector, so this new relationship is a natural partnership.

“We look forward to supporting their growth and playing our part in helping men to receive the medication they need to treat a variety of health conditions.

“Indeed it’s extremely satisfying to see Titan helping change the healthcare sector in a number of ways. Among our community pharmacy customers, efficiency savings are freeing up time to help them refocus their efforts, away from back office tasks and out front with patient care. That can only be a good thing for their businesses and for the wider NHS.

“Meanwhile our Enterprise clients are revolutionizing the way that patients can access medications online, with increased safety. So it’s been a good year for everyone at Invatech Health and we look forward to continuing the pharmacy revolution in 2022.”

More For You

Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK

Each year about 175 women travel from Wales to England for care

Wales ranked worst for second-trimester abortion access in the UK

A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.

Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.

Keep ReadingShow less
The fund offers £150 per eligible child - for up to three children per household.

The fund offers £150 per eligible child - for up to three children per household.

Charity reopens funding to ease back to school financial pressures for community pharmacists

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)

The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician

Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less
Amandeep Doll RPS  New Director of England

Amandeep Doll

RPS announces new director of England

Amandeep Doll has been named as the new director for England at the Royal Pharmaceutical Society (RPS).

The role of Director for England drives professional leadership for the pharmacy profession in England, and leads on national policy development and advocacy across England, in partnership with the English Pharmacy Board.

Keep ReadingShow less